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PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS
ABSTRACT
Pneumococcal disease is a healthcare concern with increasing financial and
societal burden for adults over the age of 65 years and their caretakers. The Center for Disease
Control and Prevention (CDC) recommends the use of pneumococcal vaccines in this population
as a preventive measure helping minimize the mortality and morbidity. This project aimed at
increasing the rate of pneumococcal vaccines in a Federally Qualified Health Center
(FQHC). The interventions implemented included the use of audit, feedback and provider
educational intervention aimed at increasing the knowledge and the intent to change and improve
their practice. The key results indicated an increase in aggregate pneumococcal vaccines in the
organization as well as an increase in individual and historical vaccination rates for the
organization and individual providers. The implications for practice include the improvement in
vaccination rates significantly impacting the health of the community, as well as an increase in
education provided regarding vaccination. The questionnaire provided positive feedback on the
intervention. Further research to determine vaccination availability and re-vaccination should be
considered.
Keywords: pneumococcal vaccine, older adults, chart audit, and provider feedback.
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SECTION ONE: INTRODUCTION
Pneumococcal disease is a healthcare concern that could be detrimental to the health of
the population, exposing an increasing financial and societal burden for adults over the age of 65
years and their caretakers. The use of pneumococcal vaccines is a preventive measure helping
minimize the mortality and morbidity in this population, as well as improving the quality of life
of individuals (Mangen, Huijts, Bonten & de Wit, 2017). The Center for Disease Control and
Prevention (CDC) recommends individuals over the age of 65 to receive the pneumococcal
vaccine to prevent the severe consequences of this disease process. The selected Federally
Qualified Health Center (FQHC) for the project has a low rate of pneumococcal vaccination in
the selected population, evidencing the risks of the community. In 2016, there were 98
pneumonia (PNA) and influenza deaths in the city of Richmond, VA (CDC, n.d.). The use of
audit and feedback as a tool to improve professional practice is established as an effective way to
influence health professional behaviors (Ivers et al., 2012). The purpose of this project was to
implement a chart audit and provider educational intervention aimed at increasing the
pneumococcal vaccination rates in adults older than 65 years of age in the FQHC. The project
also evaluated the providers’ intent to improve their practice based on the information provided.
Background
PNA is an infection of the lungs and can lead to mild and severe illness in people all
ages, with higher risk in individuals 65 years of age and older (CDC, 2017a). Communityacquired pneumonia (CAP) is a common cause of hospitalization in the elderly, while invasive
pneumococcal disease (IPD) is the most severe form of pneumococcal disease (Falkenhorst,
Remschmidt, Harder, Hummers-Pradier, Wichmann & Bogdan, 2017).

10

PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS
The role of infections continues to play a crucial part in mortality of older adults, with
PNA being one of the most severe infections, especially among men and women over 85 years of
age (CDC, 2005). The CDC (2005) estimates the 30-day death rate of PNA is 11% to 70%,
depending on the type of PNA and comorbidities of the individual. In adults over the age of 65,
PNA can be deadly. Pneumococcal pneumonia kills about one out of 20 individuals who
contract it while Pneumococcal bacteremia kills about one out of five individuals infected (CDC,
2017b). Pneumococcal meningitis causes death in about one in five individuals with the disease
(CDC, 2017b).
An estimated 1.3 million annual cases of CAP affect adults over the age of 65 years,
nearly 40% of these episodes will result in a hospitalization averaging 5.6 days of inpatient
services (Brown, Harnett, Chambers & Sato, 2018). The financial burden for each episode can
reach an excess of $18,000, causing Medicare an estimated $13 billion annually (Brown et al.,
2018). This number is expected to grow with the increasing older population in the United
States since elderly residents are increasing at twice the rate of the general population (CDC,
2005). The future economic cost of PNA hospitalization could increase annually by $2.5 billion
(Drijkoningen & Rohde, 2014). CAP risk increases with age, from 18.2 cases per 1,000
person/years in the 65 to 69 year-old population, to 52.3 cases per 1,000 person/years in
individuals older than 85 years of age (Brown et al., 2018).
The Food and Drug Administration (FDA) approved two vaccines to prevent
pneumococcal disease. The Pneumococcal conjugate vaccine (PCV13 or Prevnar 13) includes
purified capsular polysaccharide of 13 serotypes of Streptococcus pneumoniae (CDC, 2017a).
The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), a randomized,
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double-blind placebo-controlled trial of 84,496 community-dwelling immunocompetent adults
over 65 years of age demonstrated:


45.6% efficacy of PCV13 against vaccine-type pneumococcal pneumonia



45.0% efficacy against vaccine-type non-bacteremic pneumococcal pneumonia



75.0% efficacy of PCV13 against vaccine-type IPD (CDC, 2017a).
The pneumococcal polysaccharide vaccine (PPSV23 or Pneumovax 23) contains antigens

from 23 types of pneumococcal bacteria (CDC, 2017a). This vaccine is 60% to 70% effective in
preventing invasive disease (CDC, 2017a). The CDC (2017a) recommends the following
guidelines in the use of pneumococcal vaccines:


Give a dose of PCV13 to adults 65 years or older who have not previously received a
dose. Then administer a dose of PPSV23 at least one year later.



If the patient already received one or more doses of PPSV23, give the dose of PCV13 at
least one year after they received the most recent dose of PPSV23.
To further support the use of the vaccines, studies show that at least one dose of

pneumococcal vaccine protects 75 in 100 older adults against invasive pneumococcal disease and
45 in 100 older adults against pneumococcal PNA (CDC, 2017a). Despite the efficacy of these
vaccines, the current rate of vaccination in the older adult population ranges from 59.7% to
66.9% (CDC, 2017a), leaving a significant percentage of the community at increased risk and
vulnerable to this disease.
Also, relevant to the project are health disparities and the incidence of chronic disease in
the elderly. In 2006, African American men older than 65 years of age were nearly 7% more
likely to die from influenza and PNA than their counterpart in the Caucasian population
(American Lung Association [ALA], 2010). These numbers exposed that African Americans are
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37% less likely than Caucasians to be vaccinated against PNA, while Hispanics are 46% less
likely to be vaccinated against PNA than Caucasians (ALA, 2010).
The project took place in a FQHC with a low rate of pneumococcal vaccination
documented in the patient’s charts. Preliminary data shows that 3% of adults over the age of 65
who were seen by providers between January 1, 2018, and June 30, 2018, have a documented
pneumococcal immunization. Documentation indicates that the vaccine was received in the
clinic. Providers can also document if the patient refused to receive the vaccine in the preventive
medicine section of the medical record; this can be determined by chart review only.
Immunizations received at another facility are documented historically in the immunization
section.
Problem Statement
Pneumococcal disease is a serious condition increasing the risks of complications and
decreasing quality of life for adults older than 65 years of age (CDC, 2017a). The CDC
recommends scheduled vaccinations in this population to prevent this complicated and possibly
fatal illness (2017a). The patients at the FQHC are at higher risk of contracting this preventable
disease due to the low rate of pneumococcal vaccines documented, but also due to the population
characteristics. Preliminary data shows only 3% of the selected population had received the
immunization this year. This fact exposes the gap in quality of care related to pneumonia
prevention in the community of individuals over 65 years of age and older.
Purpose of the Project
The purpose of this project was to implement a chart audit and provider educational
intervention aimed at increasing the Pneumococcal vaccination rates in adults older than 65 years
of age in the FQHC. The project also aimed to improve the provider’s intent to improve their
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practice related to Pneumococcal immunizations. The chart audit was used to determine
Pneumococcal vaccination practices and documentation. The educational intervention
incorporated current recommendations by the CDC, as well as resources describing efficacy,
benefits, and vaccination schedules.
Clinical Question
In providers working at a FQHC (P), does a chart audit and educational feedback
intervention (I) increase pneumococcal vaccination rate in older adults (O)?
SECTION TWO: LITERATURE REVIEW
A literature review was conducted to evaluate current guidelines for pneumococcal
vaccination, as well as effectiveness and safety. The information researched also focused on the
impact of vaccination, financial and health-related, and resources for educational interventions.
These topics were selected as all-inclusive areas of interest when analyzing PNA immunization,
overarching to provide an understanding of the possible challenges preventing vaccination in
older adults, as well as strategies to address the problem in similar settings.
Search Strategy
Pneumonia vaccine. A literature search was completed using PubMed, CINAHL, and
MEDLINE. The search strategy includes keywords: Pneumococcal vaccine, older adults,
elderly, seniors, geriatrics. The parameters of the search contained articles published in the
English language within the last five years. Peer-reviewed articles and full-text articles were
considered for review. A total of 266 articles were found. After reviewing abstracts and
synopsis, 15 articles were selected. Articles with lower Melnyk level of evidence or opinions
were excluded, from the remaining collection, the project leader chose articles in different
categories with higher Melnyk level of evidence. The first 15 articles with these characteristics
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were selected. These articles encompass the broad spectrum of the project and help understand
the need for a project to increase pneumococcal vaccination rate in primary care and its impact
on the older population.
Audit and feedback. A literature search was also completed using the same databases
utilizing the keywords audit and feedback. The parameters of the search contained articles
published in the English language within the last ten years. Peer-reviewed articles and full-text
articles were considered for review. A total of 3043 articles were found, further evaluation of
articles for systematic reviews and meta-analysis yielded 161 articles. After reviewing abstracts
and synopsis, four articles were selected based on the level of evidence and the use of both, audit
and feedback in clinical practice.
Critical Appraisal
Pneumonia vaccine. The articles selected were analyzed individually, and as a whole;
the appraisal was completed using the Melnyk Levels of Evidence. From the 15 articles
selected, five articles were level one, indicating systematic review, meta-analysis, and guidelines.
One article was level two, a random controlled trial (RTC). The next six articles belong to level
four, describing cohort studies or pilot tests. From the last three articles, one is level five and
two are level seven. These articles are used to provide background information to evaluate
possible educational content. A table of evidence for each article is located in Appendix A.
Some of the research analyzed was developed in foreign countries, which could pose some
limitations. Data analysis is also performed utilizing current CDC guidelines, which help ground
clinical practice in the United States.
The FDA licensed PCV13 in 2010 based on studies comparing serological response in
children who received PCV13 to PCV7 (CDC, 2017a). Immunogenicity and vaccine efficacy in
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older adults was conducted in the CAPiTA trial from 2008 to 2013 (CDC, 2017a). Evidence
from this trial provided signs suggesting benefits of PCV13 vaccination in older adults, resulting
in lower IPD incidence among unvaccinated persons of all ages (CDC, 2017a). Vaccination with
PPSV23 shows that more than 80% of healthy adults vaccinated develop antibodies against the
serotypes contained in the vaccine, with an immune response within two to three weeks (CDC,
2017a). The CDC (2017a) indicates that older adults, as well as people with some chronic
conditions or immunodeficiency, may not respond as well with antibodies declining quicker than
in healthy adults. Overall, PPSV23 is 60% to 70% effective in preventing invasive disease
(CDC, 2017a). The PNA vaccination rate in older adults was 63.6%, indicating that more than
six out of 10 individuals were vaccinated. This group was characterized by individuals older
than 75 years of age, non-Hispanic white, and not poor (CDC, 2017a), pointing to health
discrepancies in the health system. Based on this evidence, the literature review will focus on
vaccine immunogenicity and effectiveness, the financial and societal burden of PNA, and
strategies to increase the vaccination rate in specific settings.
The systematic review by Remschmidt, Harder, Wichmann, Bogdan & Falkenhorst
(2016) did not include any reports on the effectiveness of pneumococcal vaccination, the sections
on immunogenicity and re-vaccination are still considered in this review. Huss et al.’s (2009)
results on all-cause mortality in double-blind trials and the little evidence of vaccine protection
among the elderly contradict other research. This article was analyzed, and although a level one
on the Melkyn evidence grading, the results will not be included at this time. Several articles
were included to take notice of the financial burden of pneumococcal disease and explore, not
only the health risks of the disease but also the economic consequences, personal and societal.
The article by Drijkoningen & Rohde (2014) was included to provide clinical information in the
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disease process. This resource, along with the CDC and guidelines by the Infectious Diseases
Society of America (IDSA) and the American Thoracic Society (ATS) (Mandell et al., 2007),
provided grounded knowledge to incorporate in the educational intervention.
Audit and feedback. The articles selected were analyzed individually, and an appraisal
was completed using the Melnyk Levels of Evidence. The four articles selected are level one,
indicating systematic review and meta-analysis. These articles provide evidence of the
effectiveness of a chart audit and feedback on the improvement of professional practice (Ivers et
al., 2012)
Synthesis
Pneumonia vaccine. There were consistent reports across the articles indicating the
benefits of the pneumococcal vaccine and the risks of remaining unvaccinated. Baldo et al.
(2016) concluded that there is a high mortality rate among older patients admitted to the hospital
for pneumonia and indicated that the PCV13 vaccine has a protective role against the disease.
The study by Mangen et al. (2017) reported lower quality of life in the cohort of patients
surviving hospitalization for CAP and a six fold-increase of mortality in individuals diagnosed
with CAP. Literature also shows several categories, pointing at the full benefits of
pneumococcal immunization. These categories include (a) healthcare cost savings, (b) health
gains, (c) prevention of comorbidities, (d) risk reductions, and (d) decrease in nosocomial
infections (Cafiero-Fonseca et al., 2017).
The financial burden of contracting PNA is rising. The hospitalization rate for older
adults diagnosed with PNA in increasing, showing a 20% surge in the period between 1988-1990
and 2000-2002 (Vila-Corcoles & Ochoa-Gondar, 2015). Calculations of hospitalization costs
due to CAP are expected to be between $7000 and $8000 per episode (Vila-Corcoles & Ochoa-
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Gondar, 2015). Given these numbers and the increased elderly population, prevention is crucial.
The vaccination cost for CAP is approximately $40.2 million; this amount includes
pneumococcal and influenza vaccines (Brown et al., 2018).
Two articles were evaluated for innovating strategies that could be used in a primary care
setting to increase the rate of pneumococcal vaccination. One study evaluated the
implementation of a standing order program (SOP) for staff to assess the individuals’
immunization states, ascertain if a pneumococcal vaccine is appropriate, and administer the
vaccine (Nowalk et al., 2014). This approach is underutilized in primary care offices, but the
proper utilization and evaluation of this tools can potentially increase the vaccination rate. Park
et al. (2016) proposed the implementation of a program that would increase vaccination rates by
(a) implementing a protocol, (b) staff education, (c) identification of eligible patients, and (d)
automated outreach and immunization scheduling. Although the project was not implemented, it
offers a protocol that could be adapted to a FQHC. One major challenge would be the financial
resources to implement and sustain the plan.
Finally, and most relevant, is the data pertaining to vaccine efficacy and effectiveness.
Studies by Falkenhorst et al. (2017) and Mandell et al. (2007) support the overall effectiveness of
PCV23 against invasive pneumococcal disease on people over the age of 65 years. The article
describing the guidelines by the DSA and ATS by Mandell et al. (2007) indicated that efficacy
may decrease with age, supporting Remschmidt et al. (2016) concepts of re-vaccination. The use
of PCV13 is also reinforced as safe and effective by Deursen et al. (2018), reducing the first
episode of CAP and IPD.
Audit and feedback. The Cochrane review of audit and feedback (Ivers et al., 2012)
concluded that this process could lead to small but potentially important improvement in
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professional practice. This analysis was supported by the subsequent secondary analysis by Ivers
et. al (2014), also indicating that audit and feedback is most effective in specific circumstances
such as (a) delivered by a supervisor or respected colleague, (b) presented frequently, (c)
featuring both specific goals and action-plans, (d) aiming to decrease the targeted behavior, (e)
baseline performance is lower, and (f) recipients are non-physicians. Colquhoun et al. (2013)
also utilized the Cochrane review to evaluate the use of theories in the development and
implementation of audits and feedback. The results from the analysis indicated that the explicit
use of theories was rare (Colquhoun et al., 2013). Tuti et al. (2017) aimed at determining the
effectiveness of electronic audit and feedback and encountered that given the heterogeneity of
the studies, the effects of using an electronic approach was highly variable.
Conceptual Framework/Model
The Iowa Model was used as a conceptual framework for this project. This model
provides a guideline for the implementation of evidence-based practice (EBP) in a variety of
settings, focusing on organization and collaboration (Iowa Model Collaborative, 2017).
Permission to use the framework and its tools has been obtained (Appendix E). The Iowa Model
has several steps: (a) identify a problem, (b) form a team, (c) gather evidence, (d) critique and
synthesize the evidence, (e) determine the validity and appropriateness of the evidence, (f) pilot
change, (g) determine if the change is appropriate for practice, (h) implement, and (i)
disseminate results (Iowa Model Collaborative, 2017). This model has several key features:


Use of flowchart to guide decision-making



Use of problem-solving steps



Use of feedback loops to guide changes in processes



Interdisciplinary approach (Schaffer, Sandau & Diedrick, 2013).
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The first step in the Iowa Model is to identify a problem for the organization, either a
problem-focused or knowledge-focus trigger (Brown, 2014). Problem-focused triggers arise
from risk management and financial data, or a clinical problem; knowledge-focused triggers
derive from new research findings, or new practice guidelines are identified (Brown, 2014).
Once the problem is identified, the project leader needs to determine if it is a priority for the
organization, issued with higher volume or higher cost will have priority and will assist in the
organizational buy-in process (Brown, 2014). Then, the team is selected, with an
interdisciplinary approach, to develop, evaluate and implement the EBP change (Brown, 2014).
The next step is to gather and critique pertinent research and develop a problem question
(Brown, 2014). At that point, the team needs to determine if sufficient research exists to
implement a practice change (Brown, 2014). If there is no sufficient evidence, then further
research needs to be conducted. If the data is sufficient, a pilot test can be implemented. If the
intervention is successful, the change can be adapted to an organizational change (Brown, 2014)
and results disseminated.
The project investigated a problem-focused issue for the organization, the low rate of
pneumococcal immunization in older adults. The next step was to form a team to address this
problem. The stakeholders were selected based on the topic, and were responsible for the
development, implementation, and evaluation of the plan. The team leader was the DNP student.
The project leader was also responsible for literature review and identifying appropriate
resources. The project leader then critiqued, synthesized and evaluated the validity of data; the
information used in the project was based on EBP and current clinical guidelines. The team used
the CDC’s recommendation and scheduled immunization guidelines as a reference for all
educational interventions and resources. Once the evidence was sufficient, the project leader
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designed and implemented the intervention selected. For this project, several factors needed to
be taken into account (a) willingness of providers to participate in the project, (b) organizational
resources, (c) time constraints, and (d) consistency between different offices. The chart audit
provided aggregate and individual data to be included in the educational intervention. The
aggregate data was disseminated to all providers, and each provider received individual feedback
based on their audits. The interventions selected included providing evidence-based information
to providers in a teaching format completed in the different locations as well as resource
materials such as immunization schedules and information sheets. After the educational
intervention was finalized, the providers completed a questionnaire indicating their intent to
change their practice based on the information provided. The project leader then encouraged the
providers to implement the knowledge provided and apply guidelines into practice. The next
step in the Iowa Model was to collect and report post-intervention data. This data assisted in
determining the outcomes of the project and if the implementation was appropriate for the
practice. At this point, the project leader met with providers and the Chief Medical Officer
(CMO) to disseminate findings and obtain input. A sustainable practice change was set to
continue the analysis of performance data on a quarterly basis and report the findings during the
providers’ meetings.
Summary
The literature review yielded important information regarding pneumococcal
immunization. The benefits of the vaccine and risk of PNA were established, but still, a large
number of patients at the FQHC remain unvaccinated. The financial burden of hospitalization
and the quality of life of individuals who contracted the disease increased the risks of
comorbidities and mortality in the elderly population. The current guidelines of the CDC, and
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recommendations by DSA and ATS encouraged the implementation of strategies to ensure
pneumonia vaccination in older adults. Preventive measures are critical to ensuring that
individuals over the age of 65 years are vaccinated. The literature addressed the effectiveness
and efficacy of the pneumococcal immunization, but more research is needed regarding
interventions to increase the vaccination rate. The purpose of this project is to increase the rate of
pneumococcal immunizations in older adults in primary care. The project focused on chart
audits and feedback, as well as educational interventions for providers in the FQHC to impact the
number of individuals over 65 years of age vaccinated against PNA. The providers also
completed a questionnaire indicating their intent to change their practice based on the
information received.
SECTION THREE: METHODOLGY
Design
The EBP project followed a quasi-experimental design evaluating the rate of
pneumococcal vaccination before and after the educational intervention. This EBP project also
followed the Iowa Model to guide the process and decision-making. The selection of this project
design is congruent when randomization is not logistically feasible in the chosen setting (Harris
et al., 2006). The intervention phase was implemented in a 30-day time frame, allowing for
educational interventions and the understanding and allocation of written materials provided.
The project leader performed chart audits and feedback focusing on documentation related to
PNA vaccination for each provider in the clinics. An intervention implementing audits and
feedback is based on the assumption that healthcare professionals will modify their practice
when provided with performance feedback indicating that their clinical practice is inconsistent
with a specific target (Ivers et al., 2012). The intent to change practice survey was used to
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determine the impact of this intervention on clinical practice. This method is more effective
when the audit and feedback are provided more than once, is given verbally and in writing, and
include specific targets and an action plan (Ivers et al., 2012). The educational intervention was
implemented once IRB approval was completed. This educational intervention was focused on
providers’ practices and consisted on an instructional meeting, with information provided
verbally and in written form. The rate of pneumococcal immunization in the selected population
was collected pre-and post-intervention. This information was obtained utilizing Electronic
Medical Records (EMR) reporting and audits.
Measurable Outcomes


Outcome 1: Increase the aggregate pneumococcal vaccination rate in patients over the
age of 65 years.



Outcome 2: Increase in individual providers’ pneumococcal vaccination rate in patients
over the age of 65 years.



Outcome 3: Provider intent to change and improve their practice based on the
interventions.

Setting
The project took place at the Capital Area Health Network (CAHN), a FQHC in the
Richmond area. This FQHC offers several services: primary care, mental health, wellness,
dental and diabetes education. CAHN has six locations in the Richmond Area, each site
provides primary care services, two locations offer dental services, and one site has mental health
services. Most insurances are accepted, but a large number of patients are uninsured and
underinsured. For patients who are uninsured, payment for services is based on income and
determined by a sliding scale fee, ranging from $35 to $150 per appointment. A flat laboratory

23

PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS
fee of $15 will include all tests ordered during the appointment. The organization also accepts
Virginia Coordinate Care, a program offered by the Virginia Commonwealth University Medical
Center, for uninsured individuals who meet the financial qualifications. This program offers
access to affordable care in the Greater Richmond Area (VCU Health, n.d.). CAHN is a
community partner providing primary care services for individuals with VCC. Given the
characteristics of the population, health disparities are evident, making a gap in care and lack of
preventive services a crucial step for the health of the community.
CAHN is committed to improving the health of the community with preventive medicine
and to eliminating health disparities (CAHN, 2018). The organization’s vision is to promote
social responsibility, improve health equity, and optimize the quality of life of the community
(CAHN, 2018). These values support the project by utilizing preventive services to ensure older
adults decrease their risk of contracting PNA and reducing the associated risks. The CMO was
informed of the project in several conversations; he had verbally agreed to support the project at
the last meeting on June 2018. A copy of the project site support letter is included in Appendix
D.
Population
The project was comprised of a primary and secondary population. The primary
population consisted of the providers in the organization, four physicians and four nurse
practitioners (NP). The providers considered for the project were part of the organization during
both audit periods. The participants were contacted in person, prior to the education and
feedback intervention for recruitment. A recruitment and consent form was signed before
initiating the chart audit process. Providers were not required to participate as a job requirement,
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and their performance measures did not impact their employment. The letter of support
(Appendix D) from the organization is included.
The secondary population will consist of patients 65 years and older (Table 1). Exclusion
criteria will consist of individuals new to the practice after the intervention period.
Nath, Costigan & Hsia (2016) indicated that individuals attending FQHC are low income,
young, uninsured or Medicaid-insured, and from racial and ethnic minorities. Data for the City
of Richmond shows that in 2017, 11.5% of the population was over the age of 65 years of age,
44.2% are white, and 48.6% are African American, and 25.4% of the population live in poverty
(United States Census Bureau, 2017).
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Table 1.
Demographic information for patients over the age of 65 years of age.
All

1001

Gender
Male

403

Female

598

Race
American Indian or Alaskan Native

3

Asian

31

Native Hawaiian or other Pacific

1

Black or African American

707

White

160

Other

63

Other Pacific Islander

1

Unreported/Refused to report

32

More than one race

0

Ethnicity
Hispanic/Latino

56

Non-Hispanic /Latino

931

Refused to report

11

Insurance
Medicare Managed Care

144

Medicare Non-Managed Care

368
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Medicaid Managed Care

17

Medicaid Non-Managed Care

4

Other public payors non-managed

102

Private non-managed care

90

Note. Patient demographics. Characteristics of patients over the age of 65 years seen in the
FQHC between 01/01/2018 and 06/30/2018.
Ethical Considerations
The intervention was started after being approved by the lead institution Institutional
Review Board (IRB) (Appendix B). The project leader also obtained a letter of support from the
CMO (Appendix D), and a letter from the human resource department approving the project and
indicating that participants will not be required to participate as a job requirement, and their
performance measures will not impact their employment (Appendix E). The project leader
included the certificate from the Collaborative Institutional Training Initiative (CITI) indicating
completion of human research training (Appendix C).
Confidentiality was maintained at every step of the project. The reports did not include
patients’ identifiers. Data from the pre-and post-intervention was kept in computer files. The
information was password protected and only accessible by the project leader. Electronic files
were backed up regularly, and copies kept with the questionnaires. The questionnaire results
were stored in a safe and secure location, a locked cabinet only accessible by the project leader.
A master list (Appendix K) was being used to protect the provider’s privacy. All the data
collected will be store for three years, after this time, electronic data will be deleted using
software designed to remove all data from the storage device. Hard copies will be shredded and
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recycled. The disposal of the data will be documented indicating how and when it was
completed.
Data Collection
Data collection took place at two points in time, pre-and post-intervention, 30 days apart.
Data collection for the pre-intervention period was done in the same period the previous year.
The reports were run by the project leader and recorded utilizing the provider identification
(Appendix K) list and the chart audit form (Appendix J). The chart audit was done pre-and postintervention as well. The project leader audited up to 15 charts for patients over the age of 65
years, selecting the first 15 charts. If a provider did not see that many patients in the secondary
population, the audit was done in all patients seen. The chart audit (Appendix I) will include
documentation for pneumococcal vaccines:


Prevnar 13



Pneumovax 23



Historical immunization Prevnar 13



Historical immunization Pneumovax 23



Education provided



Refused by patient

Tools
The organization uses E-Clinical Works (ECW) as the EMR, reports, and charts were
obtained from this application. The audit process was handled via chart review and results
secured in an electronic file. The feedback process is more effective when is the data is
delivered verbally by a trusted source, and the feedback is anchored in an overarching quality
improvement structure (Agency for Healthcare Research and Quality [AHRQ], 2017). The
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feedback report was “provider friendly” and included the following components to improve
effectiveness:


Actual performance is displayed



Reports are accompanied by a specific improvement plan that facilitates goal
achievement, in this case, the educational intervention



The report format facilitates correct interpretation and highlights important patterns in
performance (AHRQ, 2017).
The Continuing Professional Development (CPD) reaction questionnaire (Appendix G) is

a tool to assess the impact of CPD activities on clinical practice (Légaré et al., 2011; Légaré et
al., 2014, Légaré et al., 2017). This questionnaire shows adequate validity and reliability, the
Cronbach’s coefficients are 0.77 to 0.85 (Légaré et al., 2017; Légaré et al., 2014). The
questionnaire is a 12-item integrated model, combining social cognitive theories for explaining
healthcare providers’ clinical behaviors through the proxy of intention (Légaré et al., 2017).
The questionnaire proposes three categories (a) intention to adopt a particular behavior, (b) belief
about their capabilities, and (c) past behavior and habits (Légaré et al., 2017). The CPD reaction
questionnaire is published with permission to use (Université Laval, 2013). The generic CPD
questionnaire was adapted by replacing the word “behavior” in each item with “prescribe
pneumococcal vaccine.” The items in the questionnaire are precoded with Likert-type scale
values (Table 2) (Légaré et al., 2017). The item score ranges from one to seven with assigned
values, strongly disagree=1, strongly agree=7; never=1, always=7 (Légaré et al., 2017)
(Appendix H).
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Table 2.
Summary of CPD-Reaction questionnaire scores on items and constructs.

Note. CPD-Reaction questionnaire score table was retrieved from Légaré, F., Freitas, A.,
Trucotte, S., Bourdas, F., Jacuques, A., Luconi, F., …Labrecque, M. (2017). Responsiveness of
a simple tool for assessing change in behavioral intention after continuing professional
development activities. PLos, One, 12(5), e0176678. doi: 10.1371/journal.pone.0176678
Intervention
Pre-intervention.


The preconception of the project originated from conversations with other providers who
acknowledged the gap in preventive services related to pneumococcal vaccines in the
older population of the center.
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In May 2018, the project leader consulted with the CMO regarding the implementation of
a scholarly project to increase the rate of pneumococcal vaccines in patients over the age
of 65 years.



The CMO verbally agreed to the project and produced a letter of support (Appendix D).



A preliminary report was requested from the IT department to determined rates of
pneumococcal vaccination for adults over 65 years of age between January 1, 2018, and
June 30, 2018. This information was used when discussing the initiative and needs
assessment in care.

 The recruitment process took place before the initiation of the chart audit process at each
provider’s office. Providers willing to participated signed a consent form (Appendix L).


The educational intervention was conducted via a presentation where the project leader
visited the different clinics on a selected day to engage with the providers and complete
the intervention.



The information for this presentation includes current pneumococcal vaccination rates
and recommendation by the CDC, the IDSA and the ATS (Mandell et al., 2007).



A chart audit was completed before the educational intervention to identify current
practices by providers, feedback of these results was included in the educational session
along with current guidelines.
Intervention.



This stage of the process was grounded in the educational intervention to increase
awareness of the current status of pneumococcal vaccination and the need to improve
preventive services.
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The presentation took place at each office; the project leader met with the providers and
presented the information, in verbal and written form.



After the educational intervention, the providers completed the CPD reaction
questionnaire.
Post-intervention.



After the intervention was completed, the project leader began the data analysis.



The analysis focused on the effectiveness of this intervention and future applicability and
sustainability if successful.



Once data was analyzed, results evaluated and implication determined, the dissemination
process began.



Project results were shared with providers and the CMO. Individual provider’s measures
were not shared with the organization or other providers.



Each provider received a report with their vaccination rate for self-assessment.

Data Analysis
Pneumococcal vaccination rate in the organization. The data analysis for this
outcome was completed by comparing the pneumococcal vaccination rate before and after the
intervention. The data obtained from the chart review and the EMR report included (a) number
of patients with documented pneumococcal vaccine in the chart, either PCV13 or PPSV23, (b)
number of patient with a documented history of receiving either PCV13 or PPSV23, (c) number
of patient receiving PNA vaccine education, and (d) number of patients refusing to receive the
vaccine. This data allowed analyzing the impact of the intervention in the ordering and
administering of the vaccine.
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Pneumococcal vaccination rate for each provider. The data analysis for this outcome
was completed by comparing the pneumococcal vaccination rate before and after the intervention
for each provider’s panel. The data obtained from the chart review and the EMR report included
(a) number of patients with documented pneumococcal vaccine in the chart, either PCV13 or
PPSV23, (b) number of patient with a documented history of receiving either PCV13 or
PPSV23, (c) number of patient receiving PNA vaccine education, and (d) number of patients
refusing to receive the vaccine.
Provider intent to change and improve their practice based on the interventions.
The data analysis for this outcome was completed by analyzing the results of the CPD
questionnaire. This information determined if the chart review, feedback, and educational
intervention precipitated a change in practice with PNA vaccination.
SECTION FOUR: RESULTS
This section presents the results of the data analysis, including the qualitative analysis of
the chart audit results and the CPD questionnaire. The demographic data is described for the
primary population. Key findings are highlighted based on the project outcomes.
The primary population consisted of eight providers (n=8), four physicians and four NPs,
in the pre- and post-intervention periods. The sample size for the secondary population preintervention was n=96 patients, while post-intervention was n=120 patients. The chart audit preintervention was completed between December 4, 2017, and January 4, 2018. The chart audit
post-intervention was completed between December 4, 2018, and January 4, 2019. One provider
left the practice before the intervention took place. The CPD questionnaire was completed by
providers on December 3, 2018, the same day the intervention took place. A total of eight
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participants (n=8) completed the CPD questionnaire after the educational intervention, with a
response rate of 100%. One questionnaire had three answers not selected with a comment noted.
Objective One: Increase Aggregate Pneumococcal Vaccination Rate
The documented pneumococcal vaccination rate pre-intervention in the organization was
n=2, with Prevnar (n=1) and Pneumovax (n=1) vaccines documented as given during this time
frame (Figure 1). The documented vaccination rate of historical pneumococcal vaccine was
n=20 (Figure 2). From this group, Prevnar (n=6) and Pneumovax (n=14) were received the
vaccines in the past.
The post-intervention audit shows n=13 individuals received a pneumococcal vaccine
during the post-intervention period (Figure 1). From this population, Prevnar (n=10) and
Pneumovax (n=3) were received during the post-intervention period. The documented
vaccination rate of historical pneumococcal vaccine was n=36 (Figure 2). From this group,
Prevnar (n=15) and Pneumovax (n=21) were documented as received in the past.
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Figure 1. Pneumococcal vaccines documented pre- and post-intervention.

Pneumococcal Vaccine Documented
Number of vaccines

12
10
8
6
4
2
0

Prevnar

Pneumovax

Pre-intervention

1

1

Post-intervention

10

3

Vaccines
Pre-intervention

Post-intervention

Figure 2. Historical pneumococcal vaccines documented pre- and post-intervention.
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Objective Two: Increase Individual Pneumococcal Vaccination
The individual outcome showed that four providers (n=4) increased the administration of
pneumococcal vaccines in the post-intervention period. The other four providers (n=4) maintain
the same rates. These providers did not provide vaccination during the pre- and postintervention periods. The historical vaccination rates were increased in five of the providers
(n=4) while two providers (n=2) maintain the same rates pre- and post-intervention. One
provider (n=1) decreased the historical vaccination rate.
Objective Three: Provider Intent to Change and Improve their Practice Based on the
Interventions
The CPD questionnaire offers insight into the provider’s intent to change and improve
their practice based on the intervention provided. This questionnaire measures construct answers
on a Likert-type scale, with scores ranging from one to seven with assigned values, strongly
disagree=1, strongly agree=7; never=1, always=7. Mean scores above the midpoint reflect more
favorable whereas those below the midpoint are less-favorable. One provider did not answer
questions two, six and nine; instead, the provider wrote a sentence. Other scores from this
provider are included in the data analysis and evaluation. The intention construct showed a score
of 7, indicating a strong intent to change practice. The social influence construct yielded a score
of 3.75 indicating low social influence in the ordering of pneumococcal vaccines in individual
practice. The construct related to belief about capabilities showed a score of 6.83, representing a
strong belief in the individual’s capability to order pneumococcal vaccines. The moral norm
construct displayed a score of 6.93, indicating strong moral reasoning on the needs of the
vaccine. Moreover, finally, the construct belief about consequence was 7, showing a strong
sense of the pneumococcal vaccine being useful and beneficial.
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SECTION FIVE: DISCUSSION
This project sought to increase the rate of pneumococcal vaccine in a FQHC by
implementing a chart audit and provider educational intervention. The project also aimed at
assessing the provider’s intent to prescribe more pneumococcal vaccines through the use of a
questionnaire. It was established that pneumococcal bacteria could cause mild to severe illness,
but it could also be deadly for adults over the age of 65 years of age, individuals with chronic
conditions, and immunocompromised (CDC, 2017a).
Implication for Practice
The project showed an increase in pneumococcal vaccines provided to patients pre- and
post-intervention (n=2, n=13 respectively). There was a noticeable increase in vaccination rates
in three providers. Although the vaccination rate did not reach a goal of 100%, it is important to
mention that an increase in vaccination can significantly impact the population. Even though
herd immunity limits the transmission of the bacteria, specific populations like the one described
in the project, do not intrinsically achieve excellent anti pneumococcal response (Berical, Harris,
Cruz, Possick & Dela Cruz, 2016), evidencing the need for effective vaccination in the adult over
65 years of age population.
There was also an increase in historical vaccination between the pre- and postintervention periods (n=20, n=36 respectively). It is unclear at this point and with the
information collected the vaccination dates. It is possible that providers, who were aware of the
project, were prescribing the vaccines due to their knowledge before the intervention.
Regardless of the administration date, the patients benefited from an increase in vaccination. It
is important to take under consideration for further research, the intervals between both vaccines,
Prevnar and Pneumovax since CDC guidelines are very specific. The impetus to use Prevnar in
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the elderly population was based on robust immunogenicity data and supported by the CAPiTA
project (Berical et al., 2016). It is important to consider also, that as life expectancy continues to
increase, this population will need to achieve vaccine efficacy in cases known to wane over time
project (Berical et al., 2016) creating concerns for future public health demands.
The sample size from the pre- and post-intervention were noticeable different (n=96,
n=120, respectively). In this case, some providers did not get to see 15 patients in the selected
secondary population in the selected timeframe. This matter could have played a part in the
lower rates noted pre-intervention.
Similar to research findings, vaccine provision was a strong predictor of individuals
receiving the vaccine (Schneeberg et al., 2014). Providers documented educating patients on the
importance of the vaccine and, in cases where the pneumococcal vaccine was not available,
education was provided to receive the vaccine on the next office visit. This problem was noted
in one of the CPD questionnaires, where one provider instead of answering questions five,
indicated that the vaccine is easy to order but “the problem sometimes is getting it.” This issue
can be addressed in the sustainability section, where an increment in vaccines ordered can be
addressed based on vaccines administered. Regardless of these problems, research shows that
recommendation from a healthcare provider is a strong predictor of vaccination (Schneeberg et
al., 2014) and the patient should be encouraged to receive the vaccines in the office or the
pharmacy, and this should be documented.
The CPD questionnaire provided information on the intent to change practice based on
the interventions provided. The results of the questionnaire provided positive feedback on the
intervention, indicating a strong desire to order more pneumococcal vaccines. As mentioned
previously, one provider did not answer three questions. Two of these questions belong to the
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social influence construct, creating a lower than expected score. The third question was included
in the beliefs about capacity construct, also lowering this score. Given this information, the
results in these two categories will need to be evaluated separately.
The process of audit and feedback was successful in increasing the rate of pneumococcal
vaccine in adults over the age of 65 years. This strategy was implemented to increase
compliance with desire practice and improve patient outcomes (Ivers et al., 2012). A strong
organizational structure and culture focused on quality improvement, and feedback can assist in
professional behavioral changes (Ivers et al., 2012) by impacting the quality of care provided.
The project had several limitations. First, the pre-intervention sample size (n=96) was
significantly smaller than the post-intervention sample size (n=120). Second, participants were
recruited from a convenient sample, lacking randomization. Third, the project was conducted in
one FQHC with limited generalizability. Four, the lack of vaccines in some locations could have
hindered the capacity of the patient from receiving the vaccine. Last, the limited time for the
educational intervention and feedback to providers could have an impact on the provider’s
enthusiasm and participation.
Sustainability
The sustainability plan to continue the practice change is influenced by the interest of the
senior management and individual providers. The successful implementation of this project can
encourage the CMO to include pneumococcal vaccination as an outcome measure being tracked
on the provider’s meetings at least every quarter. The National Committee for Quality
Assurance (NCQA) has a measure to improve processes, in this case, the National Quality
Strategy Domain: Community/Population Health measures the Pneumococcal Vaccination Status
for Older Adults. Measures from NCQA are used by FQHC for patient-center medical homes
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(PCMH) and Health Resources and Services Administration (HRSA) initiatives. One of the
main concerns is feasibility. The convenience of pneumococcal vaccination is in having the
necessary supplies in hand to offer patients the vaccine while they are in the office. This can be
challenging from a logistic standpoint due to the number of offices within the FQHC. The
organization and selected personnel need to be proactive on the vaccines ordering process and
have a delegated person to address the needs in the different offices. Offering and ensuring
patients are vaccinated is a cultural change within an organization. Any nursing staff member
can perform this task. The sustainability plan can also include nurses assessing if a vaccine was
received or if it is needed and documenting it in the patient’s chart.

This task can be addressed

during the flu season when asking the patient if they would like to receive both vaccines,
influenza and pneumococcal.
Dissemination Plan
The dissemination of the project results took several steps. First, providers were met
individually and provided with a post-intervention feedback report. This report incorporated the
pre- and post-intervention vaccination rates individually and aggregate. This printed report was
given to each provider to keep. The aggregate results were also discussed in the monthly
provider’s meeting. A discussion of the project took place, guided by the CMO and feedback
was presented to improve future endeavors.
Other nursing staff also became part of the audience for the dissemination plan. The
morning huddle meetings were selected to report the project results. This aimed at incorporating
the organization in the project and a step in the direction of cultural change. No written
information was provided, but a verbal report of the improvement in pneumococcal vaccination
was given.

PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS
Pneumococcal disease is a potential healthcare concern that could be prevented with the
use of recommended vaccinations. Focusing on the pneumococcal vaccination rate in the FQHC
addresses a cultural change to advance patient and provider outcomes. The use of a chart audit,
provider education, and feedback were successful at increasing the knowledge and the intent to
change and improve clinical practice, as well as significantly impacting the health of the
community.

41

PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS
REFERENCES
Agency for Healthcare Research and Quality. (2017). Confidential physician feedback reports:
Designing for optimal impact on performance. Retrieved from
https://www.ahrq.gov/sites/default/files/publications/files/confidreportguide_1.pdf
American Lung Association. (2010). Missed opportunities: Influenza and pneumonia
vaccination in older adults. Retrieved from
http://www.lung.org/assets/documents/research/adult-vaccination-disparities.pdf
Baldo, V., Cocchio, S., Gallo, T., Furlan, P., Romor, P., Bertoncello, C., & ... Baldovin, T.
(2016). Pneumococcal conjugated vaccine reduces the high mortality for communityacquired pneumonia in the elderly: An Italian regional experience. Plos ONE, 11(11), 111. doi:10.1371/journal.pone.0166637
Berical, A. C., Harris, D., Cruz, C. S. D., Possick, J. D., & Dela Cruz, C. S. (2016).
Pneumococcal vaccination strategies: An update and perspective. Annals of the American
Thoracic Society, 13(6), 933–944. https://doiorg.ezproxy.liberty.edu/10.1513/AnnalsATS.201511-778FR
Brown, C. G. (2014). The Iowa Model of Evidence-Based Practice to promote quality care: An
illustrated example in oncology nursing. Clinical Journal Of Oncology Nursing, 18(2),
157-159. doi:10.1188/14.CJON.157-159
Brown, J. D., Harnett, J., Chambers, R., & Sato, R. (2018). The relative burden of communityacquired pneumonia hospitalizations in older adults: A retrospective observational study
in the United States. BMC Geriatrics, 18(1), 92. doi:10.1186/s12877-018-0787-2

42

PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS
Cafiero-Fonseca, E. T., Stawasz, A., Johnson, S. T., Sato, R., & Bloom, D. E. (2017). The full
benefits of adult pneumococcal vaccination: A systematic review. Plos ONE, 12(11), 123. doi:10.1371/journal.pone.0186903
Capital Area Health Network. (2018). Welcome to Capital Area Health Network. Retrieved from
https://cahealthnet.org/about/
Center for Disease Control and Prevention. (n.d.). Morbidity and mortality weekly report
(MMWR). Retrieved from
https://wonder.cdc.gov/mmwr/mmwr_2016_38.asp?mmwr_year=2016&mmwr_week=39
&mmwr_table=4A&request=&mmwr_location=Richmond,%20Va
Center for Disease Control and Prevention. (2005). Trends in causes of death among older
persons in the United States. Retrieved from
https://www.cdc.gov/nchs/data/ahcd/agingtrends/06olderpersons.pdf
Center for Disease Control and Prevention. (2017a). Pneumococcal vaccination. Retrieved from
https://www.cdc.gov/vaccines/vpd/pneumo/hcp/index.html
Center for Disease Control and Prevention. (2017b). Adults: Protect yourself with pneumococcal
vaccines. Retrieved from https://www.cdc.gov/features/adult-pneumococcal/index.html
Colquhoun, H. L., Brehaut, J. C., Sales, A., Ivers, N., Grimshaw, J., Michie, S., & ... Eva, K. W.
(2013). A systematic review of the use of theory in randomized controlled trials of audit
and feedback. Implementation Science, 8(1), 1-8. doi:10.1186/1748-5908-8-66
Deursen, A. M. M. van, Houten, M. A. van, Webber, C., Patton, M., Scott, D., Patterson, S., …
Grobbee, D. E. (2018). The Impact of the 13-Valent Pneumococcal Conjugate Vaccine
on Pneumococcal Carriage in the Community Acquired Pneumonia Immunization Trial

43

PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS
in Adults (CAPiTA) Study. Clinical Infectious Diseases, 67(1), 42–49. https://doiorg.ezproxy.liberty.edu/10.1093/cid/ciy009
Drijkoningen, J.C. & Rohde, G U. (2014). Pneumococcal infection in adults: Burden of disease.
Clinical Microbiology and Infection, 20, 545-51. doi: 10.1111/1269-0691.12461
Harris, A. D., McGregor, J. C., Perencevich, E. N., Furuno, J. P., Zhu, J., Peterson, D. E., &
Finkelstein, J. (2006). The use and interpretation of quasi-experimental studies in medical
informatics. Journal of the American Medical Informatics Association: JAMIA, 13(1),
16–23. http://doi.org/10.1197/jamia.M1749
Iowa Model Collaborative. (2017). Iowa model of evidence-based practice: Revisions and
validation. Worldviews on Evidence-based Nursing, 14(3), 175-182.
doi:10.111/wvn.12223
Ivers, N., Jamtvedt, G., Flottorp, S., Young, J. M., Odgaard-Jensen, J., French, S. D., & ...
Oxman, A. D. (2012). Audit and feedback: Effects on professional practice and
healthcare outcomes. The Cochrane Database Of Systematic Reviews, (6), CD000259.
doi:10.1002/14651858.CD000259.pub3
Ivers, N. M., Grimshaw, J. M., Jamtvedt, G., Flottorp, S., O'Brien, M. A., French, S. D., & ...
Odgaard-Jensen, J. (2014). Growing literature, stagnant science? Systematic review,
meta-regression and cumulative analysis of audit and feedback interventions in health
care. Journal Of General Internal Medicine, 29(11), 1534-1541. doi:10.1007/s11606014-2913-y
Falkenhorst, G., Remschmidt, C., Harder, T., Hummers-Pradier, E., Wichmann, O., & Bogdan,
C. (2017). Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23)

44

PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS
against pneumococcal disease in the elderly: Systematic review and meta-analysis. Plos
ONE, 12(1), 1-18. doi:10.1371/journal.pone.0169368
Huss, A., Scott, P., Stuck, A. E., Trotter, C., & Egger, M. (2009). Efficacy of pneumococcal
vaccination in adults: a meta-analysis. CMAJ: Canadian Medical Association
Journal, 180(1), 48-58.
Legare F, Borduas F, Jacques A, Laprise R, Voyer G, Boucher A, Luconi F, Rousseau M,
Labrecque M, Sargeant J, Grimshaw J, Godin G (2011) Developing a theory-based
instrument to assess the impact of continuing professional development activities on
clinical practice: A study protocol. Implement Science.
Légaré F, Borduas F, Freitas A, Jacques A, Godin G, Luconi F, Grimshaw J and the CPD‐ KT
team (2014) Development of a simple 12-item theory-based instrument to assess the
impact of continuing professional development on clinical behavioral intentions. PLoS
ONE 9(3): e91013. doi:10.1371/journal.pone.0091013.
Légaré, F., Freitas, A., Trucotte, S., Bourdas, F., Jacuques, A., Luconi, F., …Labrecque, M.
(2017). Responsiveness of a simple tool for assessing change in behavioral intention
after continuing professional development activities. PLos, One, 12(5), e0176678. doi:
10.1371/journal.pone.0176678
Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., &
... Whitney, C. G. (2007). Infectious Diseases Society of America/American Thoracic
Society consensus guidelines on the management of community-acquired pneumonia in
adults. Clinical Infectious Diseases: An Official Publication Of The Infectious Diseases
Society Of America, 44 Suppl 2S27-S72.

45

PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS
Mangen, M. J., Huijts, S. M., Bonten, M. M., & de Wit, G. A. (2017). The impact of communityacquired pneumonia on the health-related quality-of-life in elderly. BMC Infectious
Diseases. doi:10.1186/s12879-017-2302-3
Nath JB, Costigan S, Hsia RY. (2016). Changes in demographics of patients seen at Federally
Qualified Health Centers, 2005-2014. JAMA Intern Med. 176(5), 712–714.
doi:10.1001/jamainternmed.2016.0705
Nowalk, M. P., Nolan, B. D., Nutini, J., Ahmed, F., Albert, S. M., Susick, M., & Zimmerman, R.
K. (2014). Success of the 4 pillars toolkit for influenza and pneumococcal vaccination in
adults. Journal For Healthcare Quality: Promoting Excellence In Healthcare, 36(6), 515. doi:10.1111/jhq.12020
Park, N. J., Sklaroff, L. M., Gross-Schulman, S., Hoang, K., Tran, H., Campa, D., & ...
Guterman, J. J. (2016). Innovative strategies designed to improve adult pneumococcal
immunizations in safety net patient-centered medical homes. Population Health
Management, 19(4), 240-247. doi:10.1089/pop.2015.0099
Remschmidt, C., Harder, T., Wichmann, O., Bogdan, C., & Falkenhorst, G. (2016).
Effectiveness, immunogenicity, and safety of 23-valent pneumococcal polysaccharide
vaccine revaccinations in the elderly: A systematic review. BMC Infectious Diseases.
doi:10.1186/s12879-016-2040-y
Schaffer, M. A., Sandau, K. E., & Diedrick, L. (2013). Evidence-based practice models for
organizational change: Overview and practical applications. Journal Of Advanced
Nursing, 69(5), 1197-1209. doi:10.1111/j.1365-2648.2012.06122.x
Schneeberg, A., Bettinger, J. A., McNeil, S., Ward, B. J., Dionne, M., Cooper, C., & ... Halperin,
S. A. (2014). Knowledge, attitudes, beliefs, and behaviors of older adults about

46

PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS
pneumococcal immunization, a Public Health Agency of Canada / Canadian Institutes of
Health Research Influenza Research Network (PCIRN) investigation. BMC Public
Health, 14(1), 1-16. doi:10.1186/1471-2458-14-442
Tuti, T., Nzinga, J., Njoroge, M., Brown, B., Peek, N., English, M., & ... van der Veer, S. N.
(2017). A systematic review of electronic audit and feedback: Intervention effectiveness
and use of behaviour change theory. Implementation Science. doi:10.1186/s13012-0170590-z
United States Census Bureau. (2017). Quick facts Richmond City, Virginia. Retrieved from
https://www.census.gov/quickfacts/fact/table/richmondcityvirginia/PST040217
Université Laval. (2013). A theoRy-basEd instrument to assess the impACT of continuing
professional development activities on professional behavIOr chaNge The CPD Reaction
Questionnaire. Retrieved from
https://ktcanada.ohri.ca/costars/Research/docs/CPD_Questionnaire.pdf
Vila-Corcoles, A., & Ochoa-Gondar, O. (2013). Preventing pneumococcal disease in the
elderly. Drugs & Aging, 30(5), 263-276. doi:10.1007/s40266-013-0060-5
Virginia Commonwealth University Health. (n.d.). Virginia Coordinated Care Program.
Retrieved from https://www.vcuhealth.org/vcu-medical-center/billing-andinsurance/financial-assistance/virginia-coordinated-care-program

47

48

PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS
APPENDICES
Appendix A
Evidence Table
Name: Mara Dominguez

Clinical Question: In providers working at an FQHC (P), how does an educational intervention providing evidence-based information
on pneumococcal immunizations (I), addresses pneumococcal vaccination in older adults (O)?
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Appendix H
CPD Reaction Questionnaire Scores on Items and Constructs

Note. Retrieved from Légaré, F., Freitas, A., Trucotte, S., Bourdas, F., Jacuques, A., Luconi, F.,
…Labrecque, M. (2017). Responsiveness of a simple tool for assessing change in behavioral
intention after continuing professional development activities. PLos, One, 12(5), e0176678. doi:
10.1371/journal.pone.0176678
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Appendix J

Refused

Education

Historical
PPSV23

Historical
PCV13

PPSV23

Pneumonia Vaccine Documentation
0= Documentation Not done
1= Documentation Done

PCV13

Provider Category
Code
(0=MD; 1= NP;
2=PA)

Provider ID Code

Provider Case
Number

Pneumonia Vaccine Documentation Spreadsheet Template

Running head: INCREASING PNEUMOCOCCAL IMMUNIZATION RATES IN A
FEDERALLY QUALIFIED HEALTH CENTER
Appendix K
Master List: Provider Identification

Provider Name

Assigned Provider
ID Code
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Appendix L
Participant Consent Template
CONSENT FORM
Increase in Pneumococcal vaccination in adults over 65 years of age in a Federally
Qualified Health Center
Mara Dominguez
Liberty University
School of Nursing
You are invited to be in a research study on Pneumococcal vaccination rate in adults over the age
of 65 years. You were selected as a possible participant because you are a provider at Capital
Area Health Network (CAHN) employed during the periods between 12/04/2017 to 01/03/2018
and 12/04/2018 to 01/03/2019. Please read this form and ask any questions you may have before
agreeing to be in the study.
Mara Dominguez, a doctoral candidate in the School of Nursing at Liberty University, is
conducting this study.
Background Information: The purpose of this study is to implement a chart audit, feedback,
and provider educational intervention aiming at increasing the rate of Pneumococcal vaccination
rates in adults older than 65 years of age at a Federally Qualified Health Center.
Procedures: If you agree to be in this study, I would ask you to do the following things:
1. Participate in an educational intervention lasting less than 10 minutes.
2. Participate in a chart audit feedback process lasting less than five minutes.
3. Complete a questionnaire to determine your intent to change and improve your practice
based on the information provided, taking about five minutes.
4.
Risks: The risks involved in this study are minimal, which means they are equal to the risks you
would encounter in everyday life.
Benefits: The direct benefits participants should expect to receive from taking part in this study
are to increase their knowledge about current guidelines and an insight into their current practice.
The project will provide feedback on their performance related to pneumococcal vaccination.
Benefits to society include an increase in the pneumococcal vaccination rate in adults over the
age of 65 years, decreasing morbidity and mortality in this population
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Compensation: Participants will not be compensated for participating in this study.
Confidentiality: The records of this study will be kept private. In any sort of report, I might
publish, I will not include any information that will make it possible to identify a subject.
Research records will be stored securely, and only the researcher will have access to the records.
Participant’s privacy will be maintained using a master list and providers’ identification form. A
questionnaire with provider's name will be kept locked. The provider feedback report will be deidentified, and the educational feedback will not include the individual provider performance
reports.
Data will be stored in a password protected computer and only accessible by the project leader.
The questionnaire results will be stored in a safe and secure location, locked, only accessible by
the project leader. All the data collected will be stored for three years, after this time, electronic
data will be deleted using software designed to remove all data from the storage device. Hard
copies will be shredded and recycled. The disposal of the data will be documented indicating
how and when it was completed.
Voluntary Nature of the Study: Participation in this study is voluntary. Your decision whether
or not to participate will not affect your current or future relations with Liberty University and
CAHN. If you decide to participate, you are free to not answer any question or withdraw at any
time without affecting those relationships.
How to Withdraw from the Study: If you choose to withdraw from the study, please contact
the researcher at the email address/phone number included in the next paragraph. Should you
choose to withdraw, data collected from you, will be destroyed immediately and will not be
included in this study.
Contacts and Questions: The researcher conducting this study is Mara Dominguez. You may
ask any questions you have now. If you have questions later, you are encouraged to contact her
at 703-217-1617 or mjdominguez@liberty.edu. You may also contact the researcher’s faculty
chair, Dr. Dorothy Murphy at dlmurphy1@liberty.edu.
If you have any questions or concerns regarding this study and would like to talk to someone
other than the researcher, you are encouraged to contact the Institutional Review Board, 1971
University Blvd., Green Hall Ste. 2845, Lynchburg, VA 24515 or email at irb@liberty.edu.
Please notify the researcher if you would like a copy of this information for your records.
Statement of Consent: I have read and understood the above information. I have asked
questions and have received answers. I consent to participate in the study.
______________________________________________________________________________
Signature of Participant
Date
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______________________________________________________________________________
Signature of Investigator
Date

